Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous anti-CD22 CAR-4-1BB-TCRz-transduced T lymphocytes CART22-65s

Autologous human T lymphocytes transduced with a recombinant lentiviral vector encoding a chimeric antigen receptor (CAR) consisting of an anti-CD22 human single chain variable fragment (scFv) and linked to the co-stimulatory domain 4-1BB (CD137) coupled to the zeta chain of the TCR/CD3 complex (CD3-zeta), with potential immunostimulating and antineoplastic activities. Upon reintroduction into the patient, the autologous anti-CD22 CAR-4-1BB-TCRz -transduced T lymphocytes CART22-65s express anti-CD22-CAR on their cell surfaces and bind to the CD22 antigen on tumor cell surfaces, resulting in lysis of CD22-expressing tumor cells. CD22, a B-lineage-restricted, transmembrane phosphoglycoprotein, is expressed on malignant B cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:autologous anti-CD22 CAR T cells CART22-65s
autologous anti-CD22 scFv CAR 4-1BB-TCRz-expressing T lymphocytes CART22-65s
autologous CART22-65s cells
autologous CART22-65s T cells
autologous CART22-65s-expressing T cells
Code name:CART22-65s
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search